<DOC>
	<DOCNO>NCT01780428</DOCNO>
	<brief_summary>This double-blind , randomize , multiple-dose , placebo- positive-controlled study CL-108 ( hydrocodone 7.5 mg/APAP 325 mg , promethazine 12.5 mg ) patient moderate severe pain follow surgical removal impact third molar teeth . A positive control ( Norco , commercial formulation hydrocodone 7.5 mg/APAP 325 mg ) include determine anti-emetic effect CL-108 . The efficacy CL-108 also evaluate placebo relief pain .</brief_summary>
	<brief_title>Phase III Study Safety Efficacy Cl-108 Treatment Moderate Severe Pain</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Determination likely possibly nauseaprone . Male nonpregnant nonlactating female . Surgical extraction least 2 impacted third molar teeth A female childbearing potential eligible participate study negative urine pregnancy test use acceptable method birth control . Surgical extraction least 2 impacted third molar teeth . Presence least moderate postoperative pain . Medial Condition , presence serious medical condition . Active local infection . Drug Allergy history hypersensitivity Opioid , Promethazine , Acetaminophen . Caffeine use since midnight operation . Use IND Drug within past 30 day . Previous participation study . Pregnant lactating . Employee PI , subinvestigator Charleston Labs relative employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>